UBS Group
ALT icon

UBS Group’s Altimmune ALT Stock Holding History

UBS Group’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,100
Closed -$103K – 10690
2022
Q3 		$103K Buy
+8,100
New +$120K ﹤0.01% 5676

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group's ALT Position: Q2 2026 in Review

UBS Group reduced its Altimmune (ALT) stake by 4.2% in Q2 2026, selling an estimated $115K and leaving 866,385 shares worth $2.63M. The position accounts for ﹤0.01% of the portfolio, ranked #4842.

UBS Group first reported a position in ALT in Q4 2014 and has held it in 43 quarters since. The position peaked at $15.8M in Q4 2020. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • UBS Group held 866,385 shares of Altimmune worth $2.63M as of Q2 2026.
  • UBS Group sold 38,383 Altimmune shares in Q2 2026, an estimated $115K.
  • Altimmune made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4842 holding.
  • UBS Group first reported a position in Altimmune in Q4 2014 and has held it in 43 quarters since.
  • UBS Group's Altimmune position peaked at $15.8M in Q4 2020.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.